Evidence map›Paper›PMID 33940327›Full record

ArticleDrug and alcohol dependence2021

Age-specific treatment effects of orexin/hypocretin-receptor antagonism on methamphetamine-seeking behavior.

Natalie E Zlebnik, Nathan A Holtz, Victoria C Lepak, Amy T Saykao, Yanan Zhang, Marilyn E Carroll

Open access · greenAbstract read
In one paragraph

Article in Drug and alcohol dependence, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Natalie E ZlebnikDepartment of Psychiatry, University of Minnesota Medical School, Minneapolis, MN, 55455, USA. Electronic address: nzlebnik@som.umaryland.edu.
Nathan A HoltzDepartment of Psychiatry, University of Minnesota Medical School, Minneapolis, MN, 55455, USA.
Victoria C LepakDepartment of Psychiatry, University of Minnesota Medical School, Minneapolis, MN, 55455, USA.
Amy T SaykaoDepartment of Psychiatry, University of Minnesota Medical School, Minneapolis, MN, 55455, USA.
Yanan ZhangResearch Triangle Institute, Research Triangle Park, NC, 27709, USA.
Marilyn E CarrollDepartment of Psychiatry, University of Minnesota Medical School, Minneapolis, MN, 55455, USA.
University of Minnesota Medical Center · USRTI International · US

Funding

Vulnerability to Drug Abuse: Experimental InterventionsR01DA003240 · NIDA · UNIVERSITY OF MINNESOTA TWIN CITIES · PI CARROLL, MARILYN E. · 1985 to 2010
$3.1M
Allosteric Modulation of the CB1 ReceptorR01DA040693 · NIDA · RESEARCH TRIANGLE INSTITUTE · PI ZHANG, YANAN · 2016 to 2020
$2.4M
Adolescence, Impulsivity, and Drug Abuse: Sex/HormonesR01DA019942 · NIDA · UNIVERSITY OF MINNESOTA · PI CARROLL, MARILYN E. · 2007 to 2012
$1.4M
Models for the Prevention and Treatment of Drug AbuseK05DA015267 · NIDA · UNIVERSITY OF MINNESOTA TWIN CITIES · PI CARROLL, MARILYN E. · 2002 to 2011
$1.3M
Effects of exercise on dopaminergic mechanisms of cocaine relapseK99DA047419 · NIDA · UNIVERSITY OF MARYLAND BALTIMORE · PI ZLEBNIK, NATALIE · 2019 to 2020
$353k
NIDA NIH HHS K05 DA015267NIDA NIH HHS K99 DA047419NIDA NIH HHS R01 DA003240NIDA NIH HHS R01 DA019942NIDA NIH HHS R01 DA040693
6 · The paper itself

Abstract

backgroundWorldwide methamphetamine (METH) use has increased significantly over the last 10 years, and in the US, METH dependence has sky-rocketed among individuals with opioid use disorder. Of significant concern, METH use is gaining popularity among groups with susceptibility to developing severe substance use disorders, such as women and adolescents. Nevertheless, there is no established pharmacotherapy for METH addiction. Emerging evidence has identified the orexin/hypocretin system as an important modulator of reward-driven behavior and a potential target for the treatment of drug addiction and relapse. However, to date, there have been no investigations into the therapeutic efficacy of orexin/hypocretin receptor antagonists for METH-motivated behavior in adolescents or adults. In the present study, we examined the effects of selective antagonists of the orexin-1 (SB-334867, 20 mg/kg) and orexin-2 (TCS-OX2-29, 20 mg/kg) receptors on the reinstatement of METH seeking in both adolescent and adult male and female rats.

methodsRats were trained to self-administer METH (0.05 mg/kg/inf, iv) during two 2-h sessions/day for 5 days. Following 20 sessions of extinction over 10 days, a within-subjects design was used to test for METH seeking precipitated by METH (1 mg/kg, ip) or METH cues after systemic pretreatment with SB-334867 or TCS-OX2-29.

resultsSB-334867 reduced cue-induced reinstatement in males and females, regardless of age. Additionally, METH-induced METH seeking was attenuated by SB-334867 in adolescents and by TCS-OX2-29 in adults.

conclusionSelective orexin/hypocretin receptor antagonists have significant therapeutic potential for diminishing METH-seeking behavior, although their treatment efficacy may be influenced by age.

Indexed as

MethamphetamineAge FactorsAnimalsDrug-Seeking BehaviorExtinction, PsychologicalFemaleMaleOrexin Receptor AntagonistsOrexinsRatsSelf AdministrationMethamphetamineOrexin Receptor AntagonistsOrexinsAdolescentHypocretinMethamphetamineOrexinReinstatementSex differences

Identifiers

PMID33940327
PMCPMC8180489
OpenAlexW3159025107

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.